Stockscreener 앱 받기
60.04
0.45%
-0.27
시간 외 거래:
58.99
-1.05
-1.75%
전일 마감가:
$60.31
열려 있는:
$60.27
하루 거래량:
1.31M
Relative Volume:
0.62
시가총액:
$7.18B
수익:
$18.47M
순이익/손실:
$-589.53M
주가수익비율:
-11.41
EPS:
-5.26
순현금흐름:
$-399.80M
1주 성능:
+5.39%
1개월 성능:
+15.46%
6개월 성능:
+58.63%
1년 성능:
+12.96%
1일 변동 폭
$58.58
$60.50
1주일 범위
$57.27
$61.48
52주 변동 폭
$29.31
$61.48
Cytokinetics Inc Stock (CYTK) Company Profile
명칭
Cytokinetics Inc
전화
(650) 624-3000
주소
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
CYTK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
60.04 | 7.22B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 재개 | Raymond James | Mkt Perform |
| 2025-04-24 | 개시 | Barclays | Overweight |
| 2025-02-07 | 개시 | Citigroup | Buy |
| 2025-01-22 | 개시 | Stifel | Buy |
| 2024-11-08 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-07 | 개시 | B. Riley Securities | Buy |
| 2023-08-15 | 개시 | SVB Securities | Outperform |
| 2023-02-17 | 개시 | BofA Securities | Neutral |
| 2022-12-23 | 재확인 | Needham | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-01-28 | 개시 | Goldman | Buy |
| 2021-12-22 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | JP Morgan | Overweight |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2021-02-18 | 개시 | Barclays | Overweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 개시 | Goldman | Neutral |
| 2020-07-10 | 개시 | Raymond James | Strong Buy |
| 2020-05-05 | 개시 | Mizuho | Buy |
| 2020-04-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 재개 | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 재확인 | Morgan Stanley | Overweight |
| 2017-11-22 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2017-11-21 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 개시 | Morgan Stanley | Overweight |
| 2017-03-08 | 개시 | Rodman & Renshaw | Buy |
| 2017-02-06 | 업그레이드 | Needham | Buy → Strong Buy |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 재확인 | Needham | Buy |
| 2015-11-10 | 재확인 | FBR Capital | Outperform |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-07-24 | 재확인 | MLV & Co | Buy |
| 2014-12-31 | 재확인 | ROTH Capital | Buy |
| 2014-11-04 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-04-28 | 재확인 | Needham | Buy |
모두보기
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
CYTK INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - FinancialContent
Bragar Eagel & Squire, P.C. Reminds Investors of VFC, Cytokinetics, Quanex, and RCI to Contact the Firm About their Rights in Filed Class Action Lawsuits - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors of VFC, Cytokinetics, Quanex, and RCI to Contact the Firm About their Rights in Filed Class Action Lawsuits - GlobeNewswire Inc.
Investors who lost money on Cytokinetics, Incorporated(CYTK) should contact Levi & Korsinsky about pending Class ActionCYTK - PR Newswire
State of Alaska Department of Revenue Decreases Stake in Cytokinetics, Incorporated $CYTK - Defense World
Weiss Ratings Reiterates "Sell (D-)" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
CYTK SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - PR Newswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionCYTK - PR Newswire
Portnoy Law Firm Announces Class Action on Behalf of Cytokinetics, Incorporated. Investors - GlobeNewswire
Deadline Alert: Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire
Cytokinetics, Incorporated Sued for Securities Law Violations - GuruFocus
How Cytokinetics Incorporated stock benefits from tech adoptionTreasury Yields & AI Enhanced Market Trend Forecasts - newser.com
Top chart patterns to watch in Cytokinetics IncorporatedWeekly Stock Report & Step-by-Step Swing Trade Plans - newser.com
Should I hold or sell Cytokinetics Incorporated stock in 2025July 2025 Summary & Low Drawdown Trading Strategies - newser.com
Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - Yahoo
Cytokinetics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment landscape - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming DeadlinesCYTK - PR Newswire
Cytokinetics, Inc. Hits New 52-Week High at $61.00 - Markets Mojo
Cytokinetics Shareholder Alert By Former Louisiana Attorney - GlobeNewswire
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 2,000 Shares - MarketBeat
ROSEN, LEADING INVESTOR COUNSEL, Encourages Cytokinetics, - GlobeNewswire
Malik, Cytokinetics evp, sells $121k in shares - Investing.com
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors of VFC, - GlobeNewswire
December 19th Options Now Available For Cytokinetics (CYTK) - Nasdaq
CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm - Morningstar
Robbins LLP Reminds Cytokinetics, Inc. Investors of the Upcoming - GuruFocus
Robbins LLP Reminds Cytokinetics, Inc. Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Against CYTK - PR Newswire
Insider Sell: Kaye Edward M. MD Sells 6,757 Shares of Cytokineti - GuruFocus
Lost Money on Cytokinetics, Incorporated (CYTK)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - GlobeNewswire
Investors in Cytokinetics, Incorporated (CYTK): Protect Your RightsContact Levi & Korsinsky Before November 17, 2025 - ACCESS Newswire
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit | FinancialContent - FinancialContent
Cytokinetics stock hits 52-week high at 59.5 USD - Investing.com
Cytokinetics stock hits 52-week high at 59.5 USD By Investing.com - Investing.com Australia
Barclays Raises Price Target for Cytokinetics (CYTK) to $82 | CY - GuruFocus
Class Action Filed Against Cytokinetics, Incorporated (CYTK)November 17, 2025 Deadline to JoinContact The Gross Law Firm - Morningstar
Lost Money on Cytokinetics, Incorporated (CYTK)? Contact Levi & Korsinsky Before November 17, 2025 to Join Class Action - ACCESS Newswire
Lost Money on Cytokinetics, Incorporated (CYTK)? Join Class Action Before November 17, 2025Contact Levi & Korsinsky - ACCESS Newswire
Can Cytokinetics Incorporated (KK3A) stock sustain breakout momentumEarnings Recap Report & Real-Time Volume Triggers - newser.com
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit - Eastern Progress
ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics, - GlobeNewswire
ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel ... - Caledonian Record
J. Safra Sarasin Holding AG Grows Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Cytokinetics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Cytokinetics, IncorporatedCYTK - MarketScreener
Cytokinetics Incorporated (CYTK) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Levi & Korsinsky Reminds Cytokinetics, Incorporated Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 17, 2025CYTK - NewMediaWire
Portnoy Law Firm Announces Class Action on Behalf of Cytokinetics, Inc. Investors - GlobeNewswire
Cytokinetics Inc (CYTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cytokinetics Inc 주식 (CYTK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Oct 07 '25 |
Sale |
60.56 |
2,000 |
121,120 |
140,610 |
| Kaye Edward M. MD | Director |
Oct 06 '25 |
Sale |
60.00 |
6,757 |
405,420 |
9,778 |
5.74%
자본화:
|
볼륨(24시간):